Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation.

[1]  E. Romagnoli,et al.  Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. , 2012, Journal of the American College of Cardiology.

[2]  B. Gersh.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial , 2012 .

[3]  M. Valgimigli,et al.  Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. , 2012, JACC. Cardiovascular interventions.

[4]  G. Stone,et al.  Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  S. Mehta,et al.  Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. , 2011, European heart journal.

[6]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[7]  S. Yusuf,et al.  Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  K. Alexander,et al.  In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. , 2011, The American journal of cardiology.

[9]  S. Deftereos,et al.  Transradial access as first choice for primary percutaneous coronary interventions: experience from a tertiary hospital in Athens. , 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[10]  Sunil V. Rao,et al.  Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. , 2011, American heart journal.

[11]  S. Kaul,et al.  Trial and error. How to avoid commonly encountered limitations of published clinical trials. , 2010, Journal of the American College of Cardiology.

[12]  I. Ungi,et al.  Transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction Systematic overview and meta-analysis. , 2009, American heart journal.

[13]  Salim Yusuf,et al.  Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. , 2009, American heart journal.

[14]  S. Yusuf,et al.  Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. , 2008, American heart journal.

[15]  J. Ivanov,et al.  Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience. , 2008, American heart journal.

[16]  Fang-Shu Ou,et al.  Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. , 2008, JACC. Cardiovascular interventions.

[17]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[18]  J D Hilton,et al.  Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) , 2008, Heart.

[19]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[20]  Sanjay Kaul,et al.  Trial and error. How to avoid commonly encountered limitations of published clinical trials. , 2010, Journal of the American College of Cardiology.

[21]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[22]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[23]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[24]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[25]  W Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.

[26]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[27]  R. Califf,et al.  Prognostic value of the admission electrocardiogram in acute coronary syndromes. , 1999, JAMA.

[28]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.